DESTINY of Immunotherapy in Patients With HER2 Mutant Lung Cancer: Case Report

Immunotherapy has significantly transformed the landscape of non-oncogene-driven NSCLC. Multiple trials have reported that immunotherapy, either alone or in combination with chemotherapy, can induce pathologic complete responses-essentially tumor eradication-in non-oncogene-driven patients, at least in resectable stages. In contrast, tumors with specific molecular alterations, such as <i>EGFR</i> mutations or <i>ALK</i> rearrangements, are generally considered refractory to immune checkpoint inhibitors. Data on other lung cancer drivers, including <i>HER2</i> mutations, are scarce and limited to retrospective series, raising the question of whether immunotherapy should be avoided in all oncogene-addicted lung cancers. Here, we present the case of a patient with advanced <i>HER2</i> mutant NSCLC who achieved complete pathologic response to chemoimmunotherapy. Our observation suggests that not all driver mutations equally drive resistance to immunotherapy, and some molecular events, such as <i>HER2</i> mutations, need additional investigations.